HC Wainwright Reiterates “Buy” Rating for Aligos Therapeutics (NASDAQ:ALGS)

Aligos Therapeutics (NASDAQ:ALGS)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $75.00 target price on the stock.

Aligos Therapeutics Stock Down 10.2 %

ALGS opened at $9.14 on Friday. The stock’s 50 day moving average price is $13.19 and its two-hundred day moving average price is $16.24. The firm has a market capitalization of $713.93 million, a P/E ratio of -7.14 and a beta of 2.18. Aligos Therapeutics has a 12-month low of $8.70 and a 12-month high of $30.00.

Aligos Therapeutics (NASDAQ:ALGS) last announced its earnings results on Tuesday, August 6th. The company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.00) by $4.75. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. The business had revenue of $1.06 million for the quarter. During the same period last year, the firm posted ($10.75) EPS. As a group, analysts anticipate that Aligos Therapeutics will post -8.15 earnings per share for the current year.

Institutional Investors Weigh In On Aligos Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC lifted its position in shares of Aligos Therapeutics by 17.6% in the 1st quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock worth $644,000 after acquiring an additional 98,628 shares during the period. Opaleye Management Inc. bought a new position in Aligos Therapeutics in the fourth quarter worth $861,000. Altitude Crest Partners Inc. acquired a new stake in Aligos Therapeutics during the fourth quarter worth $1,889,000. Finally, Armistice Capital LLC bought a new stake in Aligos Therapeutics in the 4th quarter valued at $4,538,000. 60.43% of the stock is owned by institutional investors and hedge funds.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).